Dare bioscience press release
WebMar 1, 2024 · SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will present at the 35 th Annual Roth Conference, being held March 12-14, 2024 in Laguna Niguel, CA. WebJan 6, 2024 · PharmaVoice: What’s top of mind for industry execs at JPM? January 6, 2024 / in News / by jrobison.
Dare bioscience press release
Did you know?
WebMar 27, 2024 · San Diego Business Journal: Sabrina Martucci Johnson, Daré's President and CEO, Named as of San Diego’s Top 50 Most Influential Women Over 50 WebJun 30, 2024 · Press Release Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides a Company Update 08-09-2024 at 8:00 AM EDT PDF Version June 30, 2024: $32.1 million in cash and cash equivalents July 2024: approximately $18.0 million in cash received subsequent to quarter-end:
WebPress Release. Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE ... WebFeb 28, 2024 · Scrip Asks…What Does 2024 Hold For Biopharma? Part 7: Clinical Trial Trends (Subscription required)
WebApr 28, 2024 · SAN DIEGO, April 28, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will participate in a panel discussion during the Infectious Disease Virtual Conference presented by Maxim Group … WebApr 26, 2024 · SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that data from the DARE-BVFREE Phase 3 study of DARE-BV1, a thermosetting vaginal gel for the treatment of bacterial vaginosis, will be presented at the 2024 American College of …
WebApr 1, 2024 · SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it received a Notice of Award of $730,722 in a grant supporting the Ovaprene® postcoital test (PCT) clinical study research from the Eunice Kennedy Shriver National Institute of Child Health …
WebOct 28, 2024 · SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced a poster presentation at the Sexual Medicine Society of North America … matthew dennison facebookWebApr 5, 2024 · April 5, 2024, 7:46 PM · 25 min read. Daré Bioscience, Inc. (NASDAQ: DARE) Q4 2024 Earnings Call Transcript March 30, 2024. Operator: Welcome to the conference call hosted by Daré Bioscience ... matthew denotter realtorWebMar 23, 2024 · SAN DIEGO, March 23, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that it will host a conference call and live webcast... matthew dennis mk donsWebFeb 13, 2024 · SAN DIEGO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE) today announced the pricing of its previously announced underwritten public offering of 5.0 million shares of its common stock and warrants to purchase up to 3.5 million shares of its common stock. matthew dennis pattersonWebOct 17, 2024 · On October 17, 2024, Dare Bioscience, Inc. ("Dare") issued a press release regarding DARE-HRT1, its investigational combination bio-identical 17?-estradiol and bio-identical... herd immunity definition basic cdcWebMar 31, 2024 · PharmaVoice: Leaders wave a magic wand at pharma’s thorniest issues herd immunity definition basic percentageWebMar 30, 2024 · Daré Bioscience, Inc. filed its 10-K on Mar 30, 2024 for the period ending Dec 31, 2024. ... Press Releases. Security Transactions. Earnings reports. New markets. New products. Corporate strategies. ... Dare Bioscience, Inc. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) ... matthew denny discus